← Back to Search

ELF Test for Non-alcoholic Fatty Liver Disease

N/A
Recruiting
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients from hepatology clinic undergoing new evaluation for NAFLD.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing whether making the results of an ELF test available to treating hepatologists will result in more appropriate and targeted use of liver biopsy in patients with elevated liver enzymes or fatty liver.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease
  • Fatty Liver Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
A diagnosis of F3-4 fibrosis based on liver biopsy or clinical diagnosis of cirrhosis.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ELF-testExperimental Treatment1 Intervention
Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
Group II: ControlActive Control1 Intervention
No intervention.

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
462 Previous Clinical Trials
168,757 Total Patients Enrolled
Gilead SciencesIndustry Sponsor
1,083 Previous Clinical Trials
842,909 Total Patients Enrolled
14 Trials studying Non-alcoholic Fatty Liver Disease
3,808 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
Winston Dunn, M.D. 2020. "The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05370053.
All > Nonalcoholic Steatohepatitis > Nash
~98 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top